title: Pulmonary fibrosis in a patient treated with erlotinib.
authors.forename: Jan-Philipp
authors.initials: JP
authors.lastname: Bach
authors.forename: Andreas M
authors.initials: AM
authors.lastname: Kiessling
authors.forename: Antje
authors.initials: A
authors.lastname: Kleinhans
authors.forename: Charis
authors.initials: C
authors.lastname: Faoro
authors.forename: Christian
authors.initials: C
authors.lastname: Gorg
authors.forename: Jorge
authors.initials: J
authors.lastname: Riera-Knorrenschild
authors.forename: Nimrod
authors.initials: N
authors.lastname: Schwella
authors.forename: Hans-Joachim
authors.initials: HJ
authors.lastname: Wagner
authors.forename: Andreas
authors.initials: A
authors.lastname: Neubauer
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D000069347:Erlotinib Hydrochloride; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D008297:Male; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use; D011658:Pulmonary Fibrosis / Q000139:chemically induced* / Q000175:diagnosis*; D011799:Quinazolines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000069347:Erlotinib Hydrochloride